What is US7803839B2, and how is it related to cobimetinib?
US7803839B2 is a U.S. patent tied to Exelixis’ (company) prior patent family activity that predates Exelixis’ later public focus on oncology programs. Cobimetinib is a MEK inhibitor, and patents that mention cobimetinib often involve chemical synthesis steps, intermediates, and/or specific compound formulations claimed in a particular jurisdiction. The “US7803839B2” identifier itself refers to the granted U.S. patent (publication and family members may exist under different numbers).
“Cobimetinib synthesis” — what exactly might the patent cover?
When searchers look up “cobimetinib synthesis” alongside a specific patent number, they usually want one (or more) of the following that are typically found inside chemical-process claims/specifications:
- A route to make cobimetinib (step-by-step process)
- The preparation of key intermediates used on the way to cobimetinib
- Conditions for reactions (reagents, solvents, temperatures, catalysts, yields)
- Purification methods for isolating cobimetinib or intermediates
- Compound definitions and structural examples that support the claimed final API
To answer precisely for US7803839B2, the relevant claims and example sections from the actual patent text would need to be checked.
How can I find the exact synthesis examples inside US7803839B2?
For chemistry/process patents like this, the most reliable way to locate the synthesis content is to:
1. Open the granted patent text for US7803839B2.
2. Scan for sections like “Examples,” “Preparation,” “Preparation of Intermediates,” or “Example X.”
3. Jump to the independent claims that include “process for preparing” or “method of preparing” language. Those typically summarize the synthesis sequence.
4. Cross-check claim definitions against the specific example numbering in the specification, since examples often correspond to claim scope.
If you want, paste the relevant excerpt or tell me whether you’re looking for (a) the overall process, (b) a particular intermediate, or (c) conditions for one step, and I can help interpret what the patent is claiming.
Where does Exelixis’ 2006 involvement come in?
People often connect “Exelixis 2006” to an earlier priority date, an early filing, or the original patent family from which later grants like US7803839B2 emerged. In patent searching, a single granted U.S. patent can trace back to:
- an earlier priority application filed years earlier (e.g., around 2006), and/or
- continuation or related filings that later matured into a granted patent.
Confirming the exact “2006” link requires checking the patent’s priority data (typically listed on the first pages of the patent).
Is there a DrugPatentWatch.com page for this patent, and can it help?
DrugPatentWatch.com is useful when you want fast navigation across patent families, related exclusivity/patent links, and sometimes the relationship between a drug and specific patent numbers. However, I don’t have enough provided information here to reliably confirm whether DrugPatentWatch.com lists US7803839B2 specifically or how it maps to cobimetinib and Exelixis.
If you share a DrugPatentWatch.com link you found (or the drug page URL), I can help you connect it back to US7803839B2 and interpret what it indicates.
What I need from you to give the exact “cobimetinib synthesis” answer for US7803839B2
To avoid guessing, provide one of the following:
- the patent link (USPTO/Google Patents/Justia) for US7803839B2, or
- the text of the claims or the specific “Example/Preparation” section you care about, or
- the exact synthesis step/intermediate you’re trying to identify (e.g., “the nitrile formation step,” “the amide coupling,” “the cyclization,” etc.).
With that, I can extract the relevant synthesis route details from the patent and explain how the steps correspond to the claimed invention.
Sources
No sources were provided in your message, and I did not have enough information to verify US7803839B2 content or a DrugPatentWatch.com mapping.